Table 1 Clinical and treatment characteristics for maximum involvement of biopsy core (MIBC) stratified by quartile

Patients (n)

144

135

147

164

Age (y), median (IQR)

68 (62–73)

69 (63–74)

69 (62–74)

71 (64–75)

0.48*

PSA (ng/mL), median (IQR)

7.6 (5.3-10.6)

7.2 (4.9-10.4)

7.5 (5.0-12.2)

10.4 (6.7-20.4)

<0.001*

 <10

70%

73%

65%

48%

<0.0001^†

 10-20

23%

17%

25%

27%

 ≥20

7%

10%

10%

26%

T-stage

<0.0001^†

 T1-T2a

91%

92%

79%

59%

 T2b-T2c

6%

4%

17%

26%

 T3-T4

3%

4%

4%

15%

Gleason score

<0.0001^†

 2-6

67%

54%

22%

8%

 7

26%

39%

60%

49%

 8

5%

6%

10%

17%

 9-10

2%

1%

8%

26%

Percent cores positive

17% (13-33%)

25% (17-40%)

41% (25-58%)

63% (46-83%)

<0.001*

Percent cancer volume

0.8% (0.5-1.7%)

2.9% (1.9-5.0%)

11.7% (6.7-18.8%)

33.6% (20.8-48.9%)

<0.001*

NCCN risk group

<0.0001^†

 Low

52%

37%

14%

5%

 Intermediate

35%

45%

59%

39%

 High

13%

18%

27%

56%

RT dose (Gy), median (IQR)

77 (76–78)

77 (76–78)

77 (77–78)

78 (77–78)

<0.001*

Pelvic RT

12%

17%

25%

55%

<0.0001^†

ADT use

29%

31%

35%

66%

<0.0001^†

ADT duration, median (IQR)

6.9 (6.0-18.7)

6.1 (4.0-18.7)

6.4 (6.0-24.4)

20.9 (6.3-25.6)

0.2^*